Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorNarrows Institute for Biomedical Research
About this trial
To demonstrate the efficacy of Clascoterone cream 1% in reducing the size of sebaceous glands in study participants with acneiform rosacea.
Eligibility criteria
Qualifiers
Men and women ages 18+.
Diagnosis of rosacea type 2 (papulopustular).
Available and willing to comply with study instructions and attend all study visits.
Able and willing to provide written and verbal informed consent.
Disqualifiers
Subject has any skin pathology or condition that could interfere with the evaluation of the test products or requires the use of interfering topical or systemic therapy.
Subject has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this research study.
Pregnant, lactating, or is planning to become pregnant during the study.
Subject is currently enrolled in an investigational drug or device study.
Trial design
Treatments tested in this trial
- Clascoterone Cream 1%
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Narrows Institute for Biomedical Research
Lead sponsor
Sun Pharmaceutical Industries Limited
Collaborator
Source ClinicalTrials.gov